Apollo is a leading alternative asset management and retirement services platform, providing flexible financing and investment strategies to help institutions and individuals achieve long-term financial goals.
Key people at Apollo Health.
Apollo Health was founded in 1990 by Ran Ma (Founder) and Brad Menezes (Founder).
Key people at Apollo Health.
# Apollo Health Ventures: Transforming Healthcare Through Early-Stage Biotech Investment
Apollo Health Ventures is a transatlantic early-stage venture capital firm dedicated to identifying and co-founding transformative healthcare companies that tackle age-related diseases and the aging process itself.[1][2] Operating with offices in Berlin, Luxembourg, and Boston, the firm combines traditional venture funding with an active venture-building approach to create breakthrough biotechnology solutions aimed at extending healthy lifespans while reducing healthcare costs.[1]
The firm's investment philosophy centers on a dual-track strategy: actively co-founding companies through their proprietary Venture Lab while simultaneously identifying and backing best-in-class companies from external dealflow.[2][4] This hybrid model allows Apollo Health Ventures to acquire founder shares at nominal value in internally created ventures, offering unique upside potential to their investors, while also supporting exceptional external founders who are advancing cutting-edge science.[2]
Apollo Health Ventures was founded in 2016 as a Massachusetts-based investment firm with a laser focus on life science and biotech companies.[6] The firm was established by co-founders Nils Regge and Dr. Ole Mensching, who recognized a critical gap in the venture ecosystem: the need for investors who could bridge scientific expertise with capital and operational support to commercialize breakthrough aging research.[4]
The firm's evolution reflects a deliberate strategy to build a transatlantic presence. By establishing offices across Europe (Berlin and Luxembourg) and North America (Boston), Apollo Health Ventures positioned itself to access the world's leading aging research institutions and scientific talent while maintaining proximity to both European and US capital markets and regulatory environments.[5][6] This geographic diversification has proven strategic, as the firm has successfully launched multiple ventures and backed portfolio companies across both continents.
Apollo Health Ventures' most distinctive feature is its active venture creation capability. Rather than passively waiting for founders to approach them, the firm partners directly with leading scientists, research institutes, and universities to transform untapped technologies into commercial companies.[2][4] This approach mitigates risk through what the firm calls "killer experiments"—rigorous validation before full company launch—while securing founder equity at nominal value, creating asymmetric return potential for limited partners.
The firm's team combines deep scientific knowledge with operational acumen. Beyond capital deployment, Apollo Health Ventures provides hands-on support including top-team building, R&D guidance, clinical trial strategy, and indication selection—critical capabilities for biotech companies navigating complex regulatory pathways.[2] This operational support differentiates them from traditional financial investors who lack domain expertise.
Operating across Europe and North America gives Apollo Health Ventures unparalleled access to the world's premier aging research institutions, including the Buck Institute of Aging, Fred Hutch, and Memorial Sloan Kettering Cancer Center.[4] This network advantage enables the firm to identify emerging science early and recruit world-class scientific advisors and founders.
Since 2017, Apollo Health Ventures has demonstrated consistent execution, serving as a leading player in follow-on investment rounds for portfolio companies.[2] Recent examples include backing Therini Bio's $39M Series A (May 2025), HAYA Therapeutics' $65M Series A (May 2025), and leading Booster Therapeutics' $15M seed round (October 2024).[2] This syndication strength signals confidence from co-investors and validates the firm's deal sourcing and company-building capabilities.
Apollo Health Ventures operates at the intersection of two powerful macro trends: the aging of developed economies and the acceleration of biotechnology innovation. The firm is riding the wave of increased institutional capital flowing into longevity and age-related disease research, driven by demographic pressures, rising healthcare costs, and scientific breakthroughs in understanding aging mechanisms.
The timing is particularly favorable. Governments and institutional investors are increasingly recognizing that preventive biotechnology solutions addressing aging could deliver superior returns while solving massive societal challenges. Apollo Health Ventures' focus on this space positions it as a key infrastructure player in what many consider the next major venture-backed wave following software and AI.
By actively co-founding companies rather than just investing, Apollo Health Ventures also influences the broader ecosystem by democratizing access to capital for academic scientists. Traditionally, brilliant researchers lacked the entrepreneurial networks or business acumen to commercialize their work. The firm's venture lab model removes this friction, enabling more scientific breakthroughs to reach patients faster. This approach has ripple effects: it attracts top talent to the biotech sector, validates emerging research areas, and creates proof points that encourage other investors to enter the space.
Apollo Health Ventures is well-positioned to become a defining player in the longevity biotech ecosystem over the next decade. The firm's combination of scientific credibility, operational support, and transatlantic reach creates a defensible competitive advantage in an increasingly crowded venture landscape.
Looking ahead, several trends will likely shape the firm's trajectory. First, regulatory tailwinds around aging-related indications will accelerate—as more companies demonstrate efficacy in extending healthspan, regulatory agencies will develop clearer pathways for approval, reducing risk for investors. Second, consolidation and follow-on funding will favor firms with strong syndication networks and operational expertise, both of which Apollo Health Ventures possesses. Third, the convergence of AI and biotech will create new opportunities for data-driven precision medicine companies like YEARS (a portfolio company), positioning Apollo Health Ventures' portfolio for outsized returns.
The firm's challenge will be scaling its venture lab model without diluting quality or losing the scientific rigor that defines its brand. As competition intensifies and capital floods into longevity, Apollo Health Ventures' ability to maintain founder relationships, recruit top scientific talent, and execute disciplined venture creation will determine whether it becomes a tier-one player or remains a respected specialist.
Ultimately, Apollo Health Ventures represents a new archetype of venture capital: science-led, operationally intensive, and mission-driven. In an era where capital is abundant but great companies are scarce, this model—combining patient capital with deep expertise—may prove more valuable than traditional venture approaches.
Apollo Health was founded in 1990 by Ran Ma (Founder) and Brad Menezes (Founder).
